Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)

Next Previous
X
Search
Trial Profile

A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium fytate (Primary)
  • Indications Cardiovascular disorders; Vascular calcification
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CaLIPSO
  • Sponsors Laboratoris Sanifit

    • Most Recent Events

    • 11 Nov 2019 Results comparing progression of coronary artery calcium volume score and other measurements of cardiovascular calcification by CT scan during 52 weeks of treatment with SNF472 in adults patients with ESKD receiving hemodialysis published in the Circulation
    • 30 Oct 2019 According to a Sanifit media release, the top line results from this trial will be presented at the Featured Science Session of the 2019 Scientific Sessions of the American Heart Association (AHA) on 16 November 2019 in Philadelphia, Pennsylvania. The company will also host a conference call to discuss the data from this trial at 11am ET / 5pm CET / 4pm GMT on Monday 18 November.
    • 30 Oct 2019 Primary endpoint (The primary endpoint is the absolute change in coronary artery calcium volume scores measured by CT scan) has been met, according to the Sanifit media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top